Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1927 - Folfiri-Aflibercept vs Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice.

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Alessandro Ottaiano

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

A. Ottaiano1, M. Capozzi2, C. De Divitiis2, A. Cassata2, A. De Stefano2, S. Tafuto2, A. Avallone2, G. Nasti1

Author affiliations

  • 1 Ssd Innovative Therapies For Abdominal Metastases - Abdominal Oncology, Istituto Nazionale Tumori, IRCCS, Fondazione "G. Pascale", 80131 - Napoli/IT
  • 2 Abdominal Oncology, Istituto Nazionale Tumori, IRCCS, Fondazione "G. Pascale", 80131 - Naples/IT
More

Resources

Abstract 1927

Background

To date the treatment of RAS mutated (-M) metastatic colorectal cancer (mCRC) patients (pts) relies on the administration of oxaliplatin-based chemotherapy and bevacizumab as first line. Intensive debate is open about second-line treatments.

Methods

This is a real practice study; consecutive RAS-M unresectable mCRC were treated at the oncologist discretion at progression to FOLFOX/BEVA (fluorouracil, folinic acid, oxaliplatin, bevacizumab) with FOLFIRI/BEVA (fluorouracil, folinic acid, irinotecan, bevacizumab) (arm A) or FOLFIRI/AFLI (FOLFIRI, aflibercept) (arm B). We have analyzed differences in outcome and response between the two therapy sequences.

Results

Seventy-four patients were treated from January 2014 to January 2018; 31 treated with arm A, 43 with arm B. Among clinical factors there was a predominance of more extended disease (>two metastatic sites) in arm B (25/31 [51.2%] vs 40/43 [32.3 %] arm A; p = 0.0414). Fifty-nine pts were evaluable for response through RECIST: arm A, 5 PR, 15 SD, 8 PD; arm B, 5 PR, 16 SD, 10 PD. Second-line chemotherapy doses were reduced in 32.3% of pts in arm A and 38.1% in arm B. There were no grade 4 toxic events (NCI-CTC v4.0). The mean distance from first-line discontinuation to second-line start was 0.8 months in arm A and 2.4 months in arm B. Duration of first-line chemotherapy was significantly shorter in pts treated in arm B (12 pts < 6 months arm B vs 1 pt in arm A; p = 0.0278). Analysis of overall survival (OS) was done excluding these 13 pts to avoid prognostic interferences. Median OS were 22.7 in arm A vs 25.5 months in arm B (+ 2.8 months; P = 0.6855, HR: 1.12; 95% CI: 0.62 to 2.03). No maintenance treatment was done in arm B while in arm A BEVA with or without fluorouracil and folinic acid was done; censoring the analysis of OS at the end of the induction phase of both arms favored arm B (P = 0.0425; HR: 0.42; 95% CI: 0.15 to 1.15).

Conclusions

In our real practice, oncologists tend to administer FOLFIRI/AFLI in more extended RAS-M mCRC and to delay start of therapy. FOLFIRI/BEVA and FOLFIRI/AFLI are equally effective second-lines albeit FOLFIRI/AFLI, during the induction phase (6 months), is associated with a lower risk of death.

Clinical trial identification

Legal entity responsible for the study

Istituto Nazionale Tumori di Napoli, IRCCS “G. Pascale”.

Funding

Has not received any funding.

Editorial Acknowledgement

Not applicable.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings